NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free AMLX Stock Alerts $2.84 -0.04 (-1.39%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.83▼$2.9850-Day Range$2.71▼$19.5752-Week Range$2.67▼$31.77Volume1.87 million shsAverage Volume6.53 million shsMarket Capitalization$192.50 millionP/E Ratio4.06Dividend YieldN/APrice Target$38.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Amylyx Pharmaceuticals alerts: Email Address Amylyx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside1,249.8% Upside$38.33 Price TargetShort InterestBearish10.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 11 Articles This WeekInsider TradingSelling Shares$378,754 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.48) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector171st out of 939 stocksPharmaceutical Preparations Industry71st out of 444 stocks 4.1 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.33, Amylyx Pharmaceuticals has a forecasted upside of 1,249.8% from its current price of $2.84.Amount of Analyst CoverageAmylyx Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.71% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 16.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 2.8 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest80 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 135% compared to the previous 30 days.MarketBeat Follows18 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $378,754.00 in company stock.Percentage Held by Insiders11.80% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($0.48) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is 4.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is 4.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 181.32.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More AMLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Stock News HeadlinesMarch 17, 2024 | insidertrades.comInsider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Sells 4,135 Shares of StockMarch 29, 2024 | prnewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals: Hold Rating Maintained Amidst Development Shifts and Trial SetbacksMarch 27, 2024 | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLXMarch 27, 2024 | prnewswire.comApril 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against AMLXMarch 26, 2024 | prnewswire.comAMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud LawsuitMarch 26, 2024 | prnewswire.comShareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 25, 2024 | prnewswire.comINVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINEMarch 23, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AmylyxMarch 22, 2024 | prnewswire.comAMYLYX PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLXMarch 21, 2024 | prnewswire.comAMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud LawsuitMarch 21, 2024 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Recommendation of "Hold" from AnalystsMarch 20, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLXMarch 20, 2024 | stockhouse.comDEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming DeadlineMarch 20, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx PharmaceuticalsMarch 20, 2024 | prnewswire.comClass Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) - April 9, 2024 Deadline to Join - Contact Levi & KorsinskyMarch 19, 2024 | prnewswire.comAmylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXMarch 19, 2024 | americanbankingnews.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to "Neutral" at MizuhoMarch 19, 2024 | americanbankingnews.comStock Traders Buy High Volume of Amylyx Pharmaceuticals Put Options (NASDAQ:AMLX)March 18, 2024 | businesswire.comLost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law ViolationsMarch 18, 2024 | prnewswire.comAMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud LawsuitMarch 17, 2024 | markets.businessinsider.comMaintaining Hold on Amylyx Pharmaceuticals Post-PHOENIX Study Setback and Relyvrio UncertaintiesMarch 15, 2024 | prnewswire.comAMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLXMarch 15, 2024 | prnewswire.comLevi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXMarch 14, 2024 | investorplace.com3 Pharma Stocks to Sell in March Before They Crash & BurnSee More Headlines Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees384Year FoundedN/APrice Target and Rating Average Stock Price Target$38.33 High Stock Price Target$48.00 Low Stock Price Target$27.00 Potential Upside/Downside+1,249.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.70 Trailing P/E Ratio4.06 Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net Margins12.94% Pretax Margin14.26% Return on Equity12.39% Return on Assets10.68% Debt Debt-to-Equity RatioN/A Current Ratio5.66 Quick Ratio5.20 Sales & Book Value Annual Sales$380.79 million Price / Sales0.51 Cash Flow$0.59 per share Price / Cash Flow4.81 Book Value$6.42 per share Price / Book0.44Miscellaneous Outstanding Shares67,780,000Free Float59,784,000Market Cap$192.50 million OptionableOptionable Beta-0.66 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Comp: $1MMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Comp: $1MMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Comp: $695.12kMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Comp: $794.83kMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GMMr. Keith WhiteHead of Global Market AccessMore ExecutivesKey CompetitorsAdicet BioNASDAQ:ACETRepare TherapeuticsNASDAQ:RPTXscPharmaceuticalsNASDAQ:SCPHProQR TherapeuticsNASDAQ:PRQRRenovaroNASDAQ:RENBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 225,486 shares on 3/11/2024Ownership: 7.783%Joshua B CohenSold 4,135 sharesTotal: $77,448.55 ($18.73/share)James M FratesSold 1,792 sharesTotal: $33,564.16 ($18.73/share)Gina MazzarielloSold 1,540 sharesTotal: $28,844.20 ($18.73/share)Wellington Management Group LLPBought 44,753 shares on 3/5/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions AMLX Stock Analysis - Frequently Asked Questions Should I buy or sell Amylyx Pharmaceuticals stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares. View AMLX analyst ratings or view top-rated stocks. What is Amylyx Pharmaceuticals' stock price target for 2024? 8 Wall Street analysts have issued twelve-month price objectives for Amylyx Pharmaceuticals' stock. Their AMLX share price targets range from $27.00 to $48.00. On average, they predict the company's share price to reach $38.33 in the next twelve months. This suggests a possible upside of 1,249.8% from the stock's current price. View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts. How have AMLX shares performed in 2024? Amylyx Pharmaceuticals' stock was trading at $14.72 on January 1st, 2024. Since then, AMLX stock has decreased by 80.7% and is now trading at $2.84. View the best growth stocks for 2024 here. Are investors shorting Amylyx Pharmaceuticals? Amylyx Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 5,090,000 shares, an increase of 16.5% from the February 29th total of 4,370,000 shares. Based on an average daily volume of 2,790,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 10.7% of the company's stock are short sold. View Amylyx Pharmaceuticals' Short Interest. When is Amylyx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AMLX earnings forecast. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its quarterly earnings data on Thursday, February, 22nd. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. The company had revenue of $108.45 million for the quarter, compared to analysts' expectations of $106.40 million. Amylyx Pharmaceuticals had a net margin of 12.94% and a trailing twelve-month return on equity of 12.39%. During the same quarter in the prior year, the business earned ($0.65) earnings per share. What ETFs hold Amylyx Pharmaceuticals' stock? ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE). When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.81%), Vanguard Group Inc. (7.78%), Point72 Asset Management L.P. (4.07%), Stonepine Capital Management LLC (3.70%), Perceptive Advisors LLC (2.76%) and Franklin Resources Inc. (1.96%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMLX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.